.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

KOVANAZE Drug Profile

« Back to Dashboard
Kovanaze is a drug marketed by St Renatus and is included in one NDA. It is available from one supplier. There are three patents protecting this drug.

This drug has seventeen patent family members in twelve countries.

The generic ingredient in KOVANAZE is oxymetazoline hydrochloride; tetracaine hydrochloride. There are three drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the oxymetazoline hydrochloride; tetracaine hydrochloride profile page.

Summary for Tradename: KOVANAZE

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Formulation / Manufacturing:see details
Drug Prices: :see details

Pharmacology for Tradename: KOVANAZE

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
St Renatus
KOVANAZE
oxymetazoline hydrochloride; tetracaine hydrochloride
SPRAY, METERED;NASAL208032-001Jun 29, 2016RXYes9,308,191► subscribeY ► subscribe
St Renatus
KOVANAZE
oxymetazoline hydrochloride; tetracaine hydrochloride
SPRAY, METERED;NASAL208032-001Jun 29, 2016RXYes► subscribe► subscribe
St Renatus
KOVANAZE
oxymetazoline hydrochloride; tetracaine hydrochloride
SPRAY, METERED;NASAL208032-001Jun 29, 2016RXYes6,413,499► subscribe ► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: KOVANAZE

Country Document Number Estimated Expiration
Canada2757032► subscribe
Japan5788864► subscribe
Mexico2011010445► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc